The company states that chronic inflammation is closely related to many diseases and conditions associated with aging as well as arthritis, gastric reflux disease, colitis, some forms of cancer, Alzheimer's disease, immune dysfunction, etc. There is a great need for effective treatments that will be simple with no adverse side effects.
Generally, Ibuprofen (OTC) is rapidly absorbed following oral administration, and possesses a plasma half-life of approximately 2 hours with 80 % of the administered dose excreted in urine. Consequently, the immediate-release dosage of ibuprofen is 200 mg every 4-6 h, with a maximum dosage of 1200 mg over 24 hours. In simple language, there is a big demand on the market for slow release Ibuprofen.
"Spencer Pharmaceutical has developed such a slow release and unique formulation for NSAIDs controlled release, particularly Ibuprofen, under direct compression on monolithic tablet format, which are able to deliver immediately an effective dosage of the molecule and the remained dosage over a delayed period of 8-10 hours," stated Dr. Max Arella, CEO of Spencer Pharmaceutical Inc. Furthermore "The matrix (excipient) is based on natural molecules and stabilized under ionic forms. All ingredients are 100 % GRAS (generally approved as safe) and already approved as acceptable substances by FDA," pointed out Dr. Arella.
The company also points out, in vitro dissolution showed the novel monolithic tablet (600 mg) of ibuprofen is rapidly delivered in simulated gastric fluid (SGF, pH 2.0) with approximately 25 % released during the first hour and the remaining dosage of ibuprofen is sustained for released over the remaining 10 hours. The easy and non-expensive matrix developed by Spencer Pharmaceutical is currently being submitted for patent protection.
"We are excited by these new results and we are confident that many applications will be found for this new matrix developed by our scientists," commented Dr. Max Arella, CEO of Spencer Pharmaceutical.